Navigation Links
Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
Date:4/19/2011

SAN DIEGO, April 19, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that AM152, the company's lead LPA1 antagonist, has been granted an orphan drug designation by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis. Commonly referred to as IPF, this fibrotic disease affects the lungs of patients and their ability to breathe.

"This is an important development for Amira, and potentially patients suffering from IPF, as we continue to move this promising therapeutic candidate forward in development," said Bob Baltera, Chief Executive Officer.  "We are currently completing our Phase 1 studies with AM152 and expect to begin a Phase 2 study by the end of 2011 or in early 2012.  Currently there are no FDA-approved therapies for IPF, and we look forward to better understanding the potential therapeutic benefit of an LPA1 antagonist in this disease area."

AM152 is a lysophosphatidic acid (LPA) receptor 1 antagonist.  Activation of the LPA1 receptor by LPA has been implicated in a number of disease processes, including tissue fibrosis.  LPA1 receptor antagonists have displayed efficacy in a wide range of preclinical fibrosis models, including lung, skin, eye, liver and kidney.

About Orphan Drug Designation

The United States Orphan Drug Act of 1983 was created to promote and support the development of new drug therapies for diseases that affect fewer than 200,000 people in the United States.  Orphan Drug Designation provides a sponsor seven years of market exclusivity for the designated therapeutic indication in the United States, from the point at which the therapy is granted marketing approval.  Orphan Drug Designation also provides access to regulatory support from the FDA, potential FDA fee reductions and tax credits related to development expenses.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals i
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
2. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
3. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
4. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
5. Visage Imaging Releases Amira 5.3
6. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
7. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
8. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
9. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
10. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
11. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)... 2013  BioRestorative Therapies, Inc. ("BRT" or the "Company") ... developing stem cell based therapies for various personal applications, ... President and CEO, will be presenting at the Marcum ... held on Thursday, May 30, 2013 at the Grand ... New York City.  Mr. Weinreb,s presentation will take place ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
... one of New Zealand,s leading hospitals have delivered more ... in the first month of its implementation. The TrueBeam ... ) adds to Wellington Hospital,s radiotherapy capabilities and enables ... first patient in the country – and the southern ...
Belgium, United Kingdom, Austria and The Netherlands. The DORC companies employ about 300 people. Visit our website : http://www.dorc.nl  ...
Cached Medicine Technology:Wellington Hospital, New Zealand Becomes First in Southern Hemisphere to Offer Patients Fast and Precise TrueBeam Treatments 2Wellington Hospital, New Zealand Becomes First in Southern Hemisphere to Offer Patients Fast and Precise TrueBeam Treatments 3
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- The risk of ... when parents sleep with their infant, a new study ... risk for SIDS even if parents do not drink, ... of SIDS, which is a major cause of infant ... did not sleep with their babies. In the ...
(Date:5/21/2013)... Brussels proposes to include on tobacco packages in order ... on smokers because they only find some of them ... improve the efficacy of its anti-smoking campaigns, it should ... stronger emotional impact., These are some of the conclusions ... and Psychological Treatment at the University of Granada by ...
(Date:5/21/2013)... have long been known for their health benefits, ... therapies like anti-cancer drugs are delivered to specific ... uncovered how to create nanoparticles using natural lipids ... use them as drug delivery vehicles. UofL scientists ... their team today (May 21, 2013), published their ...
(Date:5/21/2013)... Tulsa, OK (PRWEB) May 21, 2013 Representatives ... has been such a success that the company has achieved ... re-launch plan from day one was to move Hammerhead Bicycles ... Company Spokesman and President Scott Robertson. , Robertson explained that ... and continue to exclusively focus on all things 29er ...
(Date:5/21/2013)... 2013 TheBeautyPlace.com helps brides to breathe ... a Big Day Kit including all the essentials a ... shine on their Wedding Day. , TheBeautyPlace.com features Wedding ... on their Wedding Day. Flowers blooming and warmer weather ... wedding season. From Memorial Day to October, brides to ...
Breaking Medicine News(10 mins):Health News:Bed-Sharing Raises SIDS Risk Fivefold, Study Finds 2Health News:Warning images for cigarette packs proposed by Europe do not make enough emotional impact 2Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Hammerhead Bicycles Now a Standalone Brand 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 3
... is pondering, , TUESDAY, July 28 (HealthDay News) -- A ... raise the age at which American women should start Pap ... age at which a woman should first have a Pap ... States, however, women are told to get regular Pap smears ...
... , LAS VEGAS, July 28 American Pacific ... will release its Fiscal 2009 third quarter financial results on Tuesday, August 4, ... to participate in a teleconference to review the financial results and outlook of ... August 4, 2009 at 1:30 p.m. PDT. To access the call please dial ...
... , , DENVER, ... around the world were honored for research projects that improved ... projects were funded through Morris Animal Foundation,s (MAF) Veterinary Student ... annual meeting in June. Members of MAF,s esteemed scientific advisory ...
... , , , ... company that is expected to become public following the planned spinoff of ... 10 registration statement for the spinoff has been declared effective by the ... The effectiveness of the Form 10 was one of the few ...
... , , DETROIT, July 28 ... net sales of $48.1 million in the first quarter of Fiscal ... corresponding period of Fiscal 2009. The reduction in sales was primarily ... period, as compared to the corresponding period of Fiscal 2009. Sales ...
... , , CUPERTINO, Calif., July 28 ... Matthew Hogan, Chief Financial Officer, will be presenting at the BMO ... 5 at 4:00 pm Eastern Time. The conference is being ... A webcast of the presentation will be accessible at: ...
Cached Medicine News:Health News:Teens May Not Benefit from Pap Tests 2Health News:Teens May Not Benefit from Pap Tests 3Health News:American Pacific to Release Financial Results and Hold Fiscal 2009 Third Quarter Investor Teleconference 2Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 2Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 3Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 4Health News:CareFusion Form 10 Registration Statement Declared Effective 2Health News:CareFusion Form 10 Registration Statement Declared Effective 3Health News:CareFusion Form 10 Registration Statement Declared Effective 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 5Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 6Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 7Health News:DURECT to Present at the BMO Capital Markets Healthcare Conference 2
Size: Medium. 22.50 mm by 24.00 mm. Clear lucite. Supplied sterile....
... 6.4 x 80 mm. Storz offers ... designed by Harvey A. Lincoff, M.D. ... cell sponge which is non-toxic and ... edges to minimize scleral intrusion. These ...
... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. The ... which is non-toxic and non-antigenic. Implants ... minimize scleral intrusion. These implants are ...
... Size: 5.0 x 2.5 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
Medicine Products: